Literature DB >> 6786862

A radioimmunoassay for a highly active luteinizing hormone-releasing hormone analogue and relation between the serum level of the analogue and that of gonadotropin.

I Yamazaki, H Okada.   

Abstract

Antisera to an LH-RH analogue, des-Gly10-[D-Leu6]-LH-RH-ethylamide (TAP-144) were produced in 10 rabbits. By using these antisera, a specific and sensitive radioimmunoassay for TAP-144 was established. Sensitivity of the radioimmunoassay ranged from 5 to 100 per assay tube with these antisera. Lh, FSH, TRH, LH-RH, and the 1-6 fragment of TAP-144 did not practically cross-react with LH-RH analogues, though the degree of the cross-reactivity differed among individual sera. The average cross-reactivity of the 10 antisera showed low specificities to TAP-144 analogues which are altered at positions 2, 3, 4, 5, and 6, but showed high specificities to those altered at positions 8 and 9. The antisera also showed low cross-reactivities to LH-RH analogues replaced at position 6 by D-amino acids and those altered at position 10 by alkylamines, but they showed fairly high cross-reactivities to analogues which are altered simultaneously at both positions 6 and 10. When TAP-144 was administered intraperitoneally to rats on the diestrous day, serum concentrations of TAP-144 increased dose-dependently but maximal serum concentrations of both LH and FSH were attained in response to higher doses of TAP-144. The peak LH and FSH concentrations appeared 70 to 110 min after the peak TAP-144 concentration had been reached. Similar delays in reaching the peak LH and FSH levels were also observed when TAP-144 was administered intravenously, subcutaneously and intramuscularly. When TAP-144 was administered intravaginally, a low but constant serum level of TAP-144 was maintained from 5 to 300 min after the administration, but serum LH and FSH levels declined to a low level from 180 min after the TAP-144 administration.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6786862     DOI: 10.1507/endocrj1954.27.593

Source DB:  PubMed          Journal:  Endocrinol Jpn        ISSN: 0013-7219


  6 in total

Review 1.  Clinical pharmacokinetics of depot leuprorelin.

Authors:  Piero Periti; Teresita Mazzei; Enrico Mini
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Pulmonary delivery of peptide drugs: effect of particle size on bioavailability of leuprolide acetate in healthy male volunteers.

Authors:  A Adjei; J Garren
Journal:  Pharm Res       Date:  1990-06       Impact factor: 4.200

3.  Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans.

Authors:  A Adjei; D Sundberg; J Miller; A Chun
Journal:  Pharm Res       Date:  1992-02       Impact factor: 4.200

4.  Reproductive dysfunction and decreased GnRH neurogenesis in a mouse model of CHARGE syndrome.

Authors:  Wanda S Layman; Elizabeth A Hurd; Donna M Martin
Journal:  Hum Mol Genet       Date:  2011-05-19       Impact factor: 6.150

Review 5.  Leuprorelin. A review of its pharmacology and therapeutic use in prostatic disorders.

Authors:  P Chrisp; E M Sorkin
Journal:  Drugs Aging       Date:  1991 Nov-Dec       Impact factor: 3.923

6.  Effect of dextran on the release of gonadotropin-releasing hormone (GnRH) injected into rats: plasma GnRH and gonadotropin response.

Authors:  N Heinrich; D Lorenz; H Berger; K Fechner; H E Schmidt; H Schäfer; B Mehlis
Journal:  Pharm Res       Date:  1985-09       Impact factor: 4.200

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.